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PRELIMINARY AND SHORT REPORTS
UNDECYLENIC ACID THERAPY IN PSORIASIS AND NEURODERMATITIS
(ATOPIC DERMATITIS)*
RICHARD Q. CROTTY, M.D. AND RICHARD S. WEiss, M.D.
Penman (1, 2) reported the use of undecylenic acidt in the treatment of psoriasis and
neurodermatitis and clearly stated that "much further investigation will be needed before
definite conclusions can be drawn." For the past five months a number of cases have been
studied in our clinics and the results are reported here.
In view of the frequency of stomach distress so often encountered during the administra-
tion of the drug, we decided to use enteric coated capsules each containing one-half gram.
Therefore to that extent the method of Perlman was modified.
The accompanying tables list the patients that were followed. Twenty-five patients with
psoriasis (Table I) and 18 patients with neurodermatitis (Table II) were studied. All of
the patients were continued on treatment for a minimum of one month. Patients that did
not return, or on whom there was an improper followup, are not included in this series.
The initial dose of undecylenic acid in all cases was kept at a relatively low level, as
toxicity from this medication had not been thoroughly investigated. Consequently, the
treatment was started with one capsule (0.5 gram) after each meal and was rapidly raised
to a total daily intake as listed in the tables. At each clinic visit (intervals of one week
in most cases) patients were interrogated as to untoward complaints and subjective im-
provement. The appearance of the lesions were described in the record at each visit. All
patients had repeated complete blood cell counts and urinalyses. In only case 3 (Table I)
was any laboratory change seen. This patient had revealed albuminuria prior to this study
and later was found to have a chronic glomerulonephritis, so the change is probably not
significant. Topical applications in the psoriasis group consisted solely of boric acid oint-
ment. In the neurodermatitis group, the patients who were not improving, required an
anti-pruritic lotion to help control the symptoms. No specific therapy was used on any
patient, other than undecylenic acid.
In the psoriasis series (Table I) the patients were classified by grading the severity of
psoriasis involvement as follows:
Grade I. Minimal scaling at sites of predisposition.
Grade II. True plaque involvement at sites of predisposition; considerable infiltration;
several inveterate areas.
Grade III. Many plaques with almost generalized involvement; considerable itching;
quite resistant to other forms of therapy.
Grade IV. Grade III plus some complications such as exfoliative dermatitis. None of
these cases was studied.
Only four patients had shown improvement in summer weather in previous years. The
remainder had shown no seasonal changes for two or more years, and one patient had
improved in the winter. Previous therapy is briefly mentioned in Table I, but consisted of
* Studies, observations and reports from the Dermatological Departments of the Barnard
Free Skin and Cancer Hospital and the School of Medicine, Washington University, St.
Louis, Missouri. Service of Richard S. Weiss, M.D.
Received for publication November 9, 1949.
f The undecylenic acid was furnished in enteric coated capsules, each containing 500
mgms., by Dumas-Wilson & Company, St. Louis, Missouri. X-ray studies of the same cap-
sules with the same enteric coating and filled with barium sulfate showed that a very small
percentage dissolved in the stomach and that all finally dissolved in the intestinal tract.
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conventional measures so further description is not necessary. Untoward complaints were
minimal in all cases studied and it was not necessary to stop therapy because of subjective
complaints in any instance.
In the neurodermatitic series (Table II) most of the descriptions of the table are similar
to those of Table I. These patients were likewise classified as to severity according to grades
as follows:
Grade I. Slightly lichenified; moderately pruritic eruption at sites of predisposition.
Grade II. Moderate lichenification; some new excoriations; severe paroxysmal itching
at sites of predisposition.
Grade III. Long standing cases with much lichenification; almost continuous itching
and spreading of lesions beyond sites of predisposition.
All of the patients in this series were classified in the group neurodermatitis disseminata
(atopic). Their ages at the time of onset varied from infancy to 37 years. Most patients
noted some seasonal variation in the early years of the disease. This phenomenon usually
disappeared several years after the onset. In this series 16 white and 2 colored patients
were studied.
SUMMARY
The effect of undecylenic acid treatment in a series of psoriasis and neurodermatitis
patients has been studied.
In the psoriasis series 25 cases were studied. Out of this group four patients experienced
100% clearing of lesions. Only one of these four patients had shown previous improvement
during summer weather in recent years. Six patients showed 50% or more improvement;
five patients showed 25% improvement. On the other hand, three patients demonstrated
no improvement but did not develop new lesions; seven patients became worse and devel.
oped new lesions despite therapy. That four out of 25 patients cleared completely is not
particularly encouraging as this has been done frequently on other therapeutic regimes.
50% or 25% improvement is to our minds relatively discouraging; we can do as well and
indeed much better with the modified Goeckerman treatment (3).
In the neurodermatitis series 18 cases were studied. Three patients experienced complete
control of the pruritus with 75% improvement of lesions. In twelve patients in this series
no improvement was seen despite length of therapy and three patients developed more
lesions and became progressively worse despite undecylenic acid therapy.
The subjective complaints and toxic signs were minimal in all cases studied and it was
not necessary to stop treatment because of untoward effects of the drug.
It is recognized that in such a small series of patients, the results are not statistically
significant. We also feel that some patients show benefit from almost any new form of treat-
ment, if their hopes are raised by the psychologic effect of strict instruction by the physician
and by newspaper and magazine reporting. When many more cases have been reported, per-
haps significant statistics will accumulate. Experimentation with undecylenic acid therapy
should be continued until its therapeutic efficacy can be thoroughly evaluated.
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